RLRelay Therapeutics, Inc. RLAY · NASDAQ
$18.34 -0.38% (-$0.07)
- Market cap
- $4.02B
- Enterprise value
- $3.93B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 388.3x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -33.7%
- Gross margin
- -566.6%
- Net margin
- -2,763.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.73
- Free float
- 78.3%
About the company
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery.
Sector
Healthcare
Industry
Biotechnology
CEO
Sanjiv K. Patel
Employees
202
Headquarters
Cambridge
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number